Internal Medicine

Laura Ross, PA-C, details her experience at the American College of Lifestyle Medicine 2021 meeting and the role of lifestyle modification in preventive medicine.

The treatment cannot be granted full approval due to ongoing litigation.

The randomized control trial investigates the effectiveness of cognitive behavioral therapy in treating chronic pain in patients who have been using opioid therapy.

Derek Jones talks about how the pandemic will shape healthcare in the coming years.

The FDA has yet to rule on twice-daily pill.

Genetic evidence show increased alcohol intake may be a causal risk factor for GA, while increased lifetime smoking was associated with risk of advanced AMD.

Proportion of eyes with IOP-related events supported monitoring in eyes treated with anti-VEGF therapy for macular edema associated with CRVO or HRVO for up to 60 months.

Phase 3 data show the solution works as fast 15 minutes and lasts for up to 6 hours, to improve near vision without impacting distance vision.

Patients in the open-label extension of the OASIS study saw increases in Inflammatory Bowel Disease Questionnaire (IBDQ) scores.

Investigators found fistulizing Crohn’s disease increases the healthcare burden and lengthens the duration of hospital stays in patients with acute kidney injuries.

It can be challenging to find a suitable donor for fecal microbiota transplantation.

Patients in both the ADVANCE and MOTIVATE studies achieved enhanced clinical response and endoscopic response.

Over the 5-year follow-up period, 94 of 170 participants had 1 or more long lapses in care, while 50 participants had short lapses only.

Patients treated with the monoclonal antibody had increased incidences of conjunctivitis, though many of these incidences were considered mild and were resolved by the end of the study.

The approval was supported by promising phase 3 data of the VOLTAIRE-X clinical trial.

Investigators call the combination of intralesional corticosteroid injections and narrow-band ultraviolet B light to be “effective, simple, and relatively safe”.

Data from the PAUSE clinical trial reveals that more participants experienced psoriasis relapse in the abatacept group than the ustekinumab group.

Dr. Robert Califf previously ran the FDA in 2016 and 2017 under former President Barack Obama.

The retina field is equipped with ideal therapy and research informing implementation. Now it needs greater patient buy-in.

Assessment from a patient survey showed an association between increased rates of injection treatment and increased restriction on usual activity for patients.

Rishi P. Singh, MD, discusses new VISTA/VIVID data showing what really influences a patients' likelihood and time to DME resolution when treated with aflibercept.

Theodore Leng, MD, MS, defines the trends of patient discontinuation, and how direct caregivers may help to reduce risk of losing patients.

Arshad Khanani, MD, MA, explains how new measures made available to ophthalmology will help address a quickly growing patient population.

Theodore Leng, MD, MS, discusses new findings based on IRIS registry data showing long-term discontinuation trends in patients.

The treatment is the first FDA approved orally-administered inhibitor of the complement C5a receptor.